Responses
Regular and young investigator award abstracts
Clinical trials in progress
428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)
Compose a Response to This Article
Other responses
No responses have been published for this article.